222 related articles for article (PubMed ID: 19140878)
1. Complement split products c3a and c4a in chronic lyme disease.
Stricker RB; Savely VR; Motanya NC; Giclas PC
Scand J Immunol; 2009 Jan; 69(1):64-9. PubMed ID: 19140878
[TBL] [Abstract][Full Text] [Related]
2. Complement split products C3a and C4a are early markers of acute lyme disease in tick bite patients in the United States.
Shoemaker RC; Giclas PC; Crowder C; House D; Glovsky MM
Int Arch Allergy Immunol; 2008; 146(3):255-61. PubMed ID: 18270493
[TBL] [Abstract][Full Text] [Related]
3. Complement activation in patients with primary antiphospholipid syndrome.
Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
[TBL] [Abstract][Full Text] [Related]
4. Anaphylatoxin levels in human aqueous humor.
Mondino BJ; Sumner H
Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
[TBL] [Abstract][Full Text] [Related]
5. [Immunological tests: Anaphylatoxins C3a, C4a, C5a].
Fujino S; Sakurabayashi I
Nihon Rinsho; 2005 Jul; 63 Suppl 7():80-3. PubMed ID: 16111194
[No Abstract] [Full Text] [Related]
6. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage.
Kasuya H; Shimizu T
J Neurosurg; 1989 Nov; 71(5 Pt 1):741-6. PubMed ID: 2809729
[TBL] [Abstract][Full Text] [Related]
7. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study.
Pfeifer PH; Brems JJ; Brunson M; Hugli TE
Immunopharmacology; 2000 Feb; 46(2):163-74. PubMed ID: 10647874
[TBL] [Abstract][Full Text] [Related]
8. Serum complement levels and severity of sepsis.
Nakae H; Endo S; Inada K; Takakuwa T; Kasai T; Yoshida M
Res Commun Chem Pathol Pharmacol; 1994 May; 84(2):189-95. PubMed ID: 8091004
[TBL] [Abstract][Full Text] [Related]
9. Unexplained intrauterine fetal death is accompanied by activation of complement.
Richani K; Romero R; Soto E; Espinoza J; Nien JK; Chaiworapongsa T; Refuerzo J; Blackwell S; Edwin SS; Santolaya-Forgas J; Mazor M
J Perinat Med; 2005; 33(4):296-305. PubMed ID: 16207114
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels and mode of excretion of the anaphylatoxins C3a and C4a in renal disease.
Abou-Ragheb HH; Williams AJ; Brown CB; Milford-Ward A
J Clin Lab Immunol; 1991 Jul; 35(3):113-9. PubMed ID: 1668764
[TBL] [Abstract][Full Text] [Related]
11. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation.
Maher SG; McDowell DT; Collins BC; Muldoon C; Gallagher WM; Reynolds JV
Ann Surg; 2011 Nov; 254(5):809-16; discussion 816-7. PubMed ID: 22005152
[TBL] [Abstract][Full Text] [Related]
12. Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma.
Marc MM; Korosec P; Kosnik M; Kern I; Flezar M; Suskovic S; Sorli J
Am J Respir Cell Mol Biol; 2004 Aug; 31(2):216-9. PubMed ID: 15039137
[TBL] [Abstract][Full Text] [Related]
13. C4A deficiency and elevated level of immune complexes: the mechanism behind increased susceptibility to systemic lupus erythematosus.
Traustadottir KH; Sigfusson A; Steinsson K; Erlendsson K
J Rheumatol; 2002 Nov; 29(11):2359-66. PubMed ID: 12415592
[TBL] [Abstract][Full Text] [Related]
14. Defective prevention of immune precipitation in autoimmune diseases is independent of C4A*Q0.
Arason GJ; Kolka R; Hreidarsson AB; Gudjonsson H; Schneider PM; Fry L; Arnason A
Clin Exp Immunol; 2005 Jun; 140(3):572-9. PubMed ID: 15932521
[TBL] [Abstract][Full Text] [Related]
15. The value of complement activation products in the assessment of systemic lupus erythematosus flares.
Porcel JM; Ordi J; Castro-Salomo A; Vilardell M; Rodrigo MJ; Gene T; Warburton F; Kraus M; Vergani D
Clin Immunol Immunopathol; 1995 Mar; 74(3):283-8. PubMed ID: 7859418
[TBL] [Abstract][Full Text] [Related]
16. Complement activation in systemic sclerosis.
Wild G; Watkins J; Ward AM; Hughes P; Hume A; Rowell NR
J Clin Lab Immunol; 1990 Jan; 31(1):39-41. PubMed ID: 1966983
[TBL] [Abstract][Full Text] [Related]
17. Complexes of IgG molecules and C3a and C4a complement components in human serum.
Nezlin R; Freywald A
Eur J Immunol; 1992 Jul; 22(7):1955-7. PubMed ID: 1623933
[TBL] [Abstract][Full Text] [Related]
18. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation.
Pfeifer PH; Kawahara MS; Hugli TE
Clin Chem; 1999 Aug; 45(8 Pt 1):1190-9. PubMed ID: 10430784
[TBL] [Abstract][Full Text] [Related]
19. [Effect of complement 4 genetic polymorphism on complement activation during cardiopulmonary bypass in open heart surgery among children].
Zhang S; Li Q; Yao S
Zhonghua Yi Xue Za Zhi; 2001 Aug; 81(15):918-20. PubMed ID: 11702666
[TBL] [Abstract][Full Text] [Related]
20. Longterm decrease in the CD57 lymphocyte subset in a patient with chronic Lyme disease.
Stricker RB; Burrascano J; Winger E
Ann Agric Environ Med; 2002; 9(1):111-3. PubMed ID: 12088407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
